Balance Sheet

Accounts Payables Accumulated Expenses Assets Capital Leases Cash & Current Investments Cash & Equivalents Common Equity Current Assets Current Deferred Revenue Current Deferred Tax Assets Current Deferred Tax Assets Current Leases Current Taxes Dividends payables Finished Goods Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Liabilities from Discontinued Operations Liabilities from Discontinued Operations Long-Term Deferred Tax Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Operating Leases Other Non-Current Assets Payables Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Retained Earnings Shareholder's Equity Shares Outstanding Short-term Investments Total Current Liabilities Total Debt Total Liabilities Treasury Shares Treasury Shares Work In Process

Cash Flow Statement

Daily Values

Growth Metrics

Others

Medifast (MED) Short term Debt (2022)

Medifast's Short term Debt history spans 6 years, with the latest figure at $27.0 million for Q2 2022.

For Q2 2022, Short term Debt changed N/A year-over-year to $27.0 million; the TTM value through Jun 2022 reached $27.0 million, changed N/A, while the annual FY2013 figure was $222000.0, 57.95% down from the prior year.
Short term Debt reached $27.0 million in Q2 2022 per MED's latest filing, up from $224000.0 in the prior quarter.
In the past five years, Short term Debt ranged from a high of $27.0 million in Q2 2022 to a low of $27.0 million in Q2 2022.